Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Leukemia, Myeloid, Acute

ClinicalTrials.gov lists 3,688 trials for Leukemia, Myeloid, Acute or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 155.

MeSH D015470 Neoplasms Neoplasm C04 C15 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1,051 Phase 1/2 Phase 1/2 491 Phase 2 Phase 2 1,036 Phase 2/3 Phase 2/3 65 Phase 3 Phase 3 283 Phase 4 Phase 4 47 Not applicable Not applicable 273 Observational Observational 419 Phase 1 Phase 1 1,051 Phase 1/2 Phase 1/2 491 Phase 2 Phase 2 1,036 Phase 2/3 Phase 2/3 65 Phase 3 Phase 3 283 Phase 4 Phase 4 47 Not applicable Not applicable 273 Observational Observational 419

Trials per phase (log scale)

2 more sections with rows

3,574 of the 3,688 trials are tagged with Leukemia, Myeloid, Acute itself; the rest are tagged with a narrower condition beneath it.

Get the Leukemia, Myeloid, Acute report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Leukemia, Myeloid, Acute trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 10 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 199

1990: 1 trials (Phase 2 1) 1991: 3 trials (Observational 1, Phase 2 1, Phase 1 1) 1992: 3 trials (Phase 2 2, Phase 1 1) 1993: 7 trials (Not applicable 1, Phase 3 3, Phase 2 3) 1994: 6 trials (Phase 3 1, Phase 2 4, Phase 1 1) 1995: 15 trials (Observational 1, Phase 3 3, Phase 2/3 1, Phase 2 4, Phase 1/2 3, Phase 1 3) 1996: 14 trials (Observational 1, Phase 4 1, Phase 3 3, Phase 2 5, Phase 1/2 1, Phase 1 3) 1997: 25 trials (Not applicable 2, Phase 3 3, Phase 2 11, Phase 1/2 3, Phase 1 6) 1998: 39 trials (Observational 1, Not applicable 2, Phase 4 3, Phase 3 6, Phase 2/3 1, Phase 2 12, Phase 1/2 4, Phase 1 10) 1999: 54 trials (Observational 4, Not applicable 3, Phase 4 1, Phase 3 10, Phase 2/3 1, Phase 2 16, Phase 1/2 3, Phase 1 16) 2000: 57 trials (Observational 2, Not applicable 5, Phase 4 2, Phase 3 7, Phase 2/3 1, Phase 2 23, Phase 1/2 6, Phase 1 11) 2001: 43 trials (Observational 4, Not applicable 4, Phase 3 2, Phase 2/3 1, Phase 2 18, Phase 1/2 6, Phase 1 8) 2002: 55 trials (Observational 4, Not applicable 5, Phase 4 1, Phase 3 12, Phase 2/3 1, Phase 2 14, Phase 1/2 6, Phase 1 12) 2003: 50 trials (Observational 5, Not applicable 6, Phase 4 2, Phase 3 2, Phase 2 19, Phase 1/2 5, Phase 1 11) 2004: 85 trials (Observational 8, Not applicable 8, Phase 3 10, Phase 2/3 4, Phase 2 25, Phase 1/2 10, Phase 1 20) 2005: 82 trials (Observational 3, Not applicable 6, Phase 4 3, Phase 3 8, Phase 2/3 1, Phase 2 29, Phase 1/2 10, Phase 1 22) 2006: 100 trials (Observational 11, Not applicable 8, Phase 4 1, Phase 3 11, Phase 2/3 3, Phase 2 37, Phase 1/2 14, Phase 1 15) 2007: 117 trials (Other 1, Observational 13, Not applicable 8, Phase 4 4, Phase 3 10, Phase 2/3 1, Phase 2 39, Phase 1/2 15, Phase 1 26) 2008: 108 trials (Observational 14, Not applicable 8, Phase 3 10, Phase 2/3 1, Phase 2 42, Phase 1/2 13, Phase 1 20) 2009: 113 trials (Other 1, Observational 11, Not applicable 7, Phase 4 2, Phase 3 5, Phase 2/3 2, Phase 2 39, Phase 1/2 16, Phase 1 30) 2010: 129 trials (Observational 25, Not applicable 6, Phase 4 5, Phase 3 12, Phase 2 34, Phase 1/2 10, Phase 1 37) 2011: 121 trials (Observational 20, Not applicable 2, Phase 3 10, Phase 2 46, Phase 1/2 16, Phase 1 27) 2012: 108 trials (Observational 10, Not applicable 5, Phase 4 1, Phase 3 7, Phase 2 33, Phase 1/2 16, Phase 1 36) 2013: 131 trials (Observational 13, Not applicable 7, Phase 4 3, Phase 3 4, Phase 2/3 3, Phase 2 49, Phase 1/2 24, Phase 1 28) 2014: 124 trials (Observational 15, Not applicable 7, Phase 3 12, Phase 2/3 1, Phase 2 26, Phase 1/2 20, Phase 1 43) 2015: 142 trials (Observational 8, Not applicable 11, Phase 4 1, Phase 3 5, Phase 2/3 5, Phase 2 45, Phase 1/2 24, Phase 1 43) 2016: 145 trials (Observational 12, Not applicable 6, Phase 4 2, Phase 3 12, Phase 2/3 2, Phase 2 35, Phase 1/2 23, Phase 1 53) 2017: 157 trials (Observational 22, Not applicable 10, Phase 4 2, Phase 3 11, Phase 2/3 1, Phase 2 39, Phase 1/2 24, Phase 1 48) 2018: 163 trials (Observational 15, Not applicable 6, Phase 3 12, Phase 2/3 8, Phase 2 43, Phase 1/2 16, Phase 1 63) 2019: 170 trials (Observational 16, Not applicable 14, Phase 4 3, Phase 3 16, Phase 2/3 1, Phase 2 40, Phase 1/2 29, Phase 1 51) 2020: 173 trials (Observational 30, Not applicable 10, Phase 3 7, Phase 2/3 3, Phase 2 37, Phase 1/2 25, Phase 1 61) 2021: 177 trials (Observational 22, Not applicable 19, Phase 3 12, Phase 2/3 3, Phase 2 40, Phase 1/2 32, Phase 1 49) 2022: 188 trials (Observational 27, Not applicable 16, Phase 4 3, Phase 3 11, Phase 2/3 2, Phase 2 35, Phase 1/2 30, Phase 1 64) 2023: 163 trials (Observational 30, Not applicable 18, Phase 3 10, Phase 2/3 3, Phase 2 33, Phase 1/2 22, Phase 1 47) 2024: 199 trials (Observational 25, Not applicable 17, Phase 4 3, Phase 3 9, Phase 2/3 2, Phase 2 53, Phase 1/2 23, Phase 1 67) 2025: 178 trials (Observational 18, Not applicable 25, Phase 4 3, Phase 3 11, Phase 2/3 3, Phase 2 42, Phase 1/2 17, Phase 1 59)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 195
2025 178
2024 199
2023 163
2022 188
2021 177
2020 173
2019 170
2018 163
2017 157

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 210 trials starting in 2026 and about 190 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 489 trials still running at the 2026-10-09 snapshot; registered median of 40 months across 2,231 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Leukemia, Myeloid, Acute trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1,051
Phase 1/2 491
Phase 2 1,036
Phase 2/3 65
Phase 3 283
Phase 4 47
Not applicable 273
Observational 419
Expanded access 22
Unknown 1

How many Leukemia, Myeloid, Acute trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 153
Recruiting 550
Enrolling by invitation 19
Active, not recruiting 214
Available 6

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Leukemia, Myeloid, Acute trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 155
Novartis Pharmaceuticals 42
AbbVie 41
Children's Oncology Group 35

Which drugs are being tested for Leukemia, Myeloid, Acute? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 269
Busulfan 168
Decitabine 155

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Cytarabine IT 470
SQ Fludarabine 347
Azacitidine MTD 320
Venetoclax 600 281
Mofetil Mycophenolate 133

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Leukemia, Myeloid, Acute trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Febrile neutropenia 5,623 293
Pneumonia 2,815 231
Sepsis 2,366 345
Anemia 2,357 62
Platelet count decreased 2,066 99

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Leukemia, Myeloid, Acute? (1,769)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignancies. Blood advances 2026 Yes
Quizartinib for Newly Diagnosed <i>FLT3</i>-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026 Yes
Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML. Blood 2026 Yes
Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026 Yes
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025 Yes

Showing 5 of 1,769 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (21)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Acute myeloid leukemia Annual incidence 1-9 / 100 000 United States US Unspecified
Acute myeloid leukemia Annual incidence 1-9 / 100 000 United States US Exact
Acute myeloid leukemia Annual incidence 1-9 / 100 000 United States US Exact
Acute myeloid leukemia Annual incidence 1-9 / 100 000 Worldwide Not stated Unspecified
Acute myeloid leukemia Annual incidence 1-9 / 100 000 Denmark Not stated Exact

Showing 5 of 21 prevalence observations.

Start your 14-day trial Email me all 21 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Acute myeloid leukemia 519 Exact Orphanet Rare Disease Ontology (ORDO)
Acute myeloid leukemia 519 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (7)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages